Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of JNJ-88549968 to use in people with myeloproliferative neoplasms. Examples of these cancers include myelofibrosis and essential thrombocythemia. In addition, their cancers have a change (mutation) in the CALR gene.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.
Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.
Liver stereotactic ablative radiotherapy (L-SABR) is a standard treatment that uses radiation therapy to target tumors that have spread to the liver while limiting the radiation dose to surrounding organs. L-SABR may also boost the immune response.
Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
The purpose of this study is to find the best dose of NXC-201 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
